Drug intelligence / Profile preview

CG-0985

Development stage: Preclinical
Lead developer: Shanghai CureGene Pharmaceutical
Modality: Small Molecules

Overview

CG-0985 is a small molecule antiviral candidate developed by CureGene Pharmaceutical. It acts as an inhibitor of the viral RNA-dependent RNA polymerase (RdRp), an essential enzyme for the replication and transcription of many RNA viruses. The drug is being developed as a broad-spectrum antiviral treatment for respiratory infections. As of the latest pipeline information, CG-0985 is in the preclinical stage of development.

Targets

RdRp (Coronavirus RNA-dependent RNA polymerase)

Beyond the preview

Go deeper on CG-0985.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG-0985.

Explore the full profile